HCA Healthcare Faces Steeper Exchange Headwinds as Patients Flock to Uninsured

HCA's second-quarter report revolved around a single, ugly dynamic: the expiration of enhanced premium tax credits sent exchange patients into the uninsured pool nearly 1-for-1, driving a $400 million EBITDA hit and forcing a second guidance cut. The stock, already down 13% over the past 90 days, fell further after the call.

The Exchange Shock

Health insurance exchanges were the story. Samuel Hazen set the tone: “Unfortunately, the enhanced premium tax credits expired at the end of the year, and the effects as expected were that many people became uninsured and still needed emergency care from hospitals.” — Samuel N. Hazen, Chief Executive Officer (CEO) · 2026-07-24 CFO Mike Marks quantified the damage: “The significant payer mix shift related to the exchanges has had an unfavorable impact on adjusted EBITDA of approximately $400 million in the quarter.” — Michael A. Marks, Chief Financial Officer (CFO) · 2026-07-24 That includes a $75 million upward revision to Q1's estimate.

The revision stems from a sharper-than-expected migration: “we originally assumed that about 80 to 85% of the patients who lose exchange coverage would become uninsured. And our data is telling us now that it is closer to 1-for-1.” — Michael A. Marks, Chief Financial Officer (CFO) · 2026-07-24 This payer mix shift – exchange patients turning uninsured – now accounts for roughly 80% of uninsured volume growth, with the remainder from slower Medicaid conversions in Texas.

That stands in stark contrast to the January guidance, when Mike assumed a 15-20% migration to employer-sponsored coverage: “we thought that we would lose about 15% to 20% of volume, of people leaving the exchanges.” — Mike Marks, Chief Financial Officer · 2026-04-24 Reality: virtually everyone goes to uninsured. In the April call, Mike had already cautioned that the $600–$900 million range was "based on what we've learned in first quarter" “we still believe that, that $600 million to $900 million range is appropriate” — Mike Marks, Chief Financial Officer · 2026-04-24 – but the data now pushes that range to $1.0–$1.2 billion.

Volume and Surgery Weakness

Elective surgery volumes tumbled, particularly on the outpatient side. Inpatient elective surgery fell 6% YTD, versus a 2% decline last year. Emergency-driven inpatient surgeries, about two-thirds of the total, were up 2%. Sam Hazen linked the decline to affordability: “HICS demand which is a big piece of our elective declines on both inpatient and outpatient is a part of it.” — Samuel N. Hazen, Chief Executive Officer (CEO) · 2026-07-24 The Inpatient surgery dynamic reinforces the incremental net benefit offset from Medicaid supplemental payments, but that's a one-off – a $540 million Florida program recognized in Q2 will not repeat at the same level.

Resiliency and Cost Management

Despite the demand pressure, HCA's financial resiliency program delivered flat same-facility costs per equivalent admission. Mike: “our total cash total cost per adjusted admission... we are only up about call it, flat to slightly up over prior year.” — Michael A. Marks, Chief Financial Officer (CFO) · 2026-07-24 This financial resiliency program is expected to bend the cost curve in H2 and into 2027. Management remains confident it can offset some of the exchange drag, but the sheer size of the migration leaves a profit gap.

We still have to take care of these patients, and we do. Our people do a wonderful job, but it does put pressure on the P&L.

Guidance and Outlook

HCA cut full-year adjusted EBITDA guidance to $15.4–$16.1B from the prior $15.6–$16.3B, reflecting an exchange headwind of -$1.0 to -$1.2B (from -$600 to -$900M) and a Medicaid supplemental net benefit of only $300–$500M. The operating margin fell 0.7pp to 12.0%, and total revenue grew just 4% yoy. Management asserts the updated guidance aligns with the 4–6% long-term EBITDA growth target, but the market remains skeptical given the sticky exchange disenrollment.

The price-to-revenue multiple of 1.4x still reflects a business that's largely executing but wrestling with a policy-driven payer mix storm.